Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8506645 | 0.88 | ACE2 (0.50) | ACE2SRD5A2AKR1C3AKR1C2GRM1 | |
| SCHEMBL27671698 | 0.87 | SRD5A2 (0.43) | ACE2SRD5A2AKR1C3AKR1C2NOTUM | |
| SCHEMBL13107113 | 0.86 | KIF11 (0.47) | ACE2AKR1C3AKR1C2NOTUMMEN1 | |
| SCHEMBL13122740 | 0.85 | NOTUM (0.42) | AKR1C3AKR1C2NOTUMRORCS1PR1 | |
| SCHEMBL20909666 | 0.85 | NOTUM (0.42) | ACE2NOTUMMEN1CYP1A2KMT2A | |
| SCHEMBL8507015 | 0.84 | ACE2 (0.53) | ACE2SRD5A2GRM1MEN1CYP1A2 | |
| SCHEMBL1807095 | 0.83 | SMN1; SMN2 (0.42) | ACE2SRD5A2AKR1C3AKR1C2NOTUM | |
| SCHEMBL16952204 | 0.82 | NOTUM (0.41) | ACE2NOTUMRORCS1PR1PDE3B | |
| SCHEMBL13122959 | 0.82 | S1PR1 (0.44) | NOTUMMEN1KMT2ARORCS1PR1 | |
| SCHEMBL3903297 | 0.82 | NOTUM (0.59) | NOTUMMEN1KMT2ATDP1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-7816348-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20070219176-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7105536-B2 | Compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-09-12 | — | — | US | disclosed |
| CN-1192022-C | Novel compound | SMITHKLINE BEECHAM PLC (GB) | 2005-03-09 | — | — | CN | disclosed |
| US-6770657-B2 | ARYL OR HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATES POSSESS ANTI-CONVULSANT ACTIVITY AND ARE THEREFORE BELIEVED TO BE USEFUL IN THE TREATMENT AND/OR PREVENTION OF MANY DISEASES | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040142964-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2004-07-22 | — | — | US | disclosed |
| EP-1367055-A1 | Isoquinolinyl carboxamides and their use as anticonvulsants | SMITHKLINE BEECHAM PLC (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-20030036551-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2003-02-20 | — | — | US | disclosed |
| US-6492388-B1 | SUCH AS N-(5-CHLORO-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)-4-ETHOXYBENZAMIDE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-10 | — | — | US | disclosed |
| US-4914123-A | Acyloxythiophene derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1990-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219176-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | ACE2 371/4885SRD5A2 1559/4885AKR1C3 1292/4885 |
| US-20030036551-A1 | Novel compounds | SCN1B, CNR1, SCN1A | ACE2 1981/4885SRD5A2 577/4885AKR1C3 1050/4885 |
| US-20040142964-A1 | Novel compounds | GRIN2C, GRIN2A, NLN | ACE2 1451/4885SRD5A2 2919/4885AKR1C3 2962/4885 |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | ACE2 371/4885SRD5A2 1559/4885AKR1C3 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.